AirSculpt Technologies NASDAQ: AIRS is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference.
AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript
AirSculpt Technologies NASDAQ: AIRS reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.
Palo Alto Networks is seeing rapid adoption of Prisma AIRS, with customer growth and larger AI security deals boosting its revenue potential.
AirSculpt Technologies NASDAQ: AIRS executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S.
AirSculpt Technologies, Inc. (AIRS) Shareholder/Analyst Call Prepared Remarks Transcript
AirSculpt Technologies NASDAQ: AIRS reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and continued debt reduction. Get AirSculpt Technologies alerts:Sign UpQ1 results: flat revenue, positive same-center sales, and margin expansion Chief Executive Officer Yogi Jashnani said the company “stabilized revenue year-over-year and delivered positive same-center sales for the first time in over two years,” while also expanding gross margin.
AirSculpt Technologies, Inc. (AIRS) Q1 2026 Earnings Call Transcript
AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
PANW's Prisma AIRS is gaining traction with rapid customer growth, rising bookings and expanding AI security capabilities supporting future growth potential.
AirSculpt Technologies, Inc. remains a Buy after a 70% stock decline, due to attractive valuation and recent buying volume. AIRS faces near-term revenue softness and must balance cost-cutting with growth initiatives, especially targeting profitable GLP-1 user segments. The company's high average ticket price (~$14k) and lack of a clear moat raise questions about long-term scalability amid inflation risks.
With deal momentum rising and integrations expanding, Prisma AIRS can emerge as a meaningful contributor to PANW's long-term growth.